PACB stock gains as PacBio highlights sequencing strength ahead Morgan Stanley conference
Published on 09/04/2026 at 13:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pacific Biosciences of California Inc. (PACB, ISIN US6932471010) stock is trading at 1.29 dollars as of September 4, 2026, giving the gene sequencing specialist a market capitalization of about 402.53 million dollars according to market data from Robinhood. At this level, the share sits between its 52-week low of 1.07 dollars and high of 2.73 dollars, underlining how far the valuation has fallen from recent peaks but also leaving room for potential recovery.
Conference appearance and technology focus
Per a GlobeNewswire release republished on September 3, 2026, PacBio management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 4:50 PM Eastern Time in New York. This scheduled appearance keeps the company visible with institutional investors and will give management a platform to discuss strategy and recent developments in long-read sequencing.
Alongside the conference agenda, PacBio has been actively promoting the capabilities of its HiFi sequencing technology. A blog post dated September 3, 2026, compares PacBio HiFi sequencing with Illumina and Oxford Nanopore across mock communities and real soil samples, concluding that HiFi delivers the most reliable results for environmental metabarcoding, a niche where accuracy and error profiles directly affect ecological and regulatory decisions. The benchmarking emphasis is important for investors because it helps justify why premium long-read platforms can defend pricing and share in a competitive market.
Stock metrics and trading picture
According to the PACB quote page on Robinhood as of September 4, 2026, the stock is trading at 1.29 dollars, with an intraday high of 1.35 dollars and a low of 1.28 dollars during the current session. At 1.29 dollars, the share price is about 0.8 percent above the day’s low and around 4.4 percent below the high, illustrating relatively contained intraday volatility despite the company’s small-cap profile.
The same data set shows a trading volume of about 5.15 million shares on September 4, 2026, compared with an average daily volume of 7.17 million shares. This puts current activity somewhat below the recent average, suggesting that while the stock remains liquid, it is not experiencing an outsized speculative spike ahead of the Morgan Stanley event. With a 52-week trading range between 1.07 dollars and 2.73 dollars, the current price of 1.29 dollars stands only about 20.6 percent above the yearly low and roughly 52.8 percent below the yearly high, a quantified illustration of the downside that long-term holders have already absorbed.
More on PACB stock and fundamentals
For investors who want to explore historical news and additional figures for Pacific Biosciences of California Inc., the thematic overview bundles recent headlines and data points around the PACB ISIN.
HiFi sequencing strengthens PacBio’s positioning
A recent article on PacBio’s corporate blog dated September 3, 2026, highlights a benchmarking study in which HiFi sequencing was compared with Illumina and Oxford Nanopore across controlled mock communities and real soil samples. In that study, PacBio’s HiFi reads generated more accurate and consistent community profiles, which is critical for environmental metabarcoding applications where misclassification can lead to flawed ecological assessments. For shareholders, this technical edge can be seen as a foundation for winning projects in academic, industrial and regulatory markets that require high confidence in variant detection.
Another piece from TradersUnion, also dated early September 2026, describes how PacBio introduced a HiFi whole-genome sequencing workflow able to deliver genome-wide variant calls in less than 30 hours. Compared with many legacy workflows that can take multiple days to reach similar coverage, this turnaround promises a quantifiable time saving of at least one day, which can matter in clinical research, newborn genomics and time-sensitive epidemiology work. By compressing the time-to-result while maintaining accuracy, PacBio is positioning its platforms as both high-quality and operationally efficient.
Product and use-case spotlight: HiFi WGS for newborn genomics
One of PacBio’s representative offerings in 2026 is its HiFi whole-genome sequencing workflow, referenced in the TradersUnion coverage of the company’s role in newborn genomics. This workflow enables genome-wide variant calls in under 30 hours and is used to generate complete genome assemblies that can support the identification of rare genetic conditions in infants. In a clinical research setting, reducing the turnaround from several days to just over one day can materially accelerate decision-making for care teams and trial designers.
PACB stock level and investor view
As of September 4, 2026, PACB stock trades on NASDAQ at 1.29 dollars, with a 52-week range between 1.07 dollars and 2.73 dollars and an indicated market capitalization of about 402.53 million dollars based on the same data snapshot. With the share price still far below the yearly high but modestly above the low, the market is pricing PacBio as a higher-risk small-cap, even as the company underscores its technology strengths and prepares to address investors at the upcoming Morgan Stanley healthcare conference.
Key data for PACB stock
- Company: Pacific Biosciences of California Inc.
- ISIN: US6932471010
- Ticker: PACB
- Trading venue: NASDAQ
- Price (as of September 4, 2026): 1.29 USD
- Market capitalization: 402.53 million USD (as of September 4, 2026)
- Sector / Industry: Health care, life sciences tools and services
- Index membership: NASDAQ composite
